智能自控手术室产品

Search documents
尚荣医疗收盘下跌1.07%,滚动市盈率175.05倍,总市值39.15亿元
Sou Hu Cai Jing· 2025-08-22 09:05
Company Overview - Shangrong Medical's closing price on August 22 was 4.63 yuan, down 1.07%, with a rolling PE ratio of 175.05 times and a total market value of 3.915 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 56.95 times and a median of 40.49 times, placing Shangrong Medical at the 112th position in industry rankings [1][2] - As of March 31, 2025, the number of shareholders was 58,323, a decrease of 621 from the previous count, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1] Business Operations - Shangrong Medical specializes in the production and sales of medical products, medical services, and health industry operations [1] - The company is recognized as one of the earliest to introduce clean technology into hospital operating rooms in China [1] - Its intelligent self-controlled operating room products have received multiple national honors, including recognition from the Ministry of Science and Technology and the Shenzhen Municipal Government [1] Patent and Innovation - The company and its subsidiaries have obtained over 180 patents, which serve as a driving force for its continuous development [1] Financial Performance - In the first quarter of 2025, Shangrong Medical reported an operating income of 280 million yuan, a year-on-year increase of 1.30%, and a net profit of 13.9642 million yuan, reflecting a year-on-year growth of 0.58% [2] - The sales gross margin for the same period was 15.27% [2]
尚荣医疗收盘上涨4.52%,滚动市盈率192.44倍,总市值43.04亿元
Sou Hu Cai Jing· 2025-08-18 19:09
深圳市尚荣医疗股份有限公司的主营业务是医疗产品生产销售、医疗服务、健康产业运营等。公司的主 要产品是医疗服务、医疗产品生产销售、健康产业运营。公司是国内最早将洁净技术引入医院手术部的 企业之一,公司的智能自控手术室产品荣获国家科技部、商务部、质量监督总局及环保总局颁发的国家 重点新产品荣誉,荣获深圳市人民政府颁发的科学技术进步二等奖,荣获深圳市科技和信息局颁发的高 新技术项目。公司是国家级高新技术企业、深圳市自主创新行业领军企业之一、深圳市高新技术企业、 深圳市知识产权优势企业。公司及子公司累计获得超过180项专利,成为公司持续发展的源动力。 8月18日,尚荣医疗今日收盘5.09元,上涨4.52%,滚动市盈率PE(当前股价与前四季度每股收益总和的 比值)达到192.44倍,创642天以来新低,总市值43.04亿元。 从行业市盈率排名来看,公司所处的医疗器械行业市盈率平均58.46倍,行业中值40.51倍,尚荣医疗排 名第113位。 股东方面,截至2025年3月31日,尚荣医疗股东户数58323户,较上次减少621户,户均持股市值35.28万 元,户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静) ...
尚荣医疗收盘下跌1.04%,滚动市盈率144.43倍,总市值32.30亿元
Sou Hu Cai Jing· 2025-07-22 09:04
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Shangrong Medical, indicating a high PE ratio compared to industry averages [1][2] - As of July 22, Shangrong Medical's stock closed at 3.82 yuan, with a PE ratio of 144.43, significantly higher than the industry average of 53.47 [1] - The company has experienced a net outflow of 279.90 thousand yuan in principal funds on July 22, with a total outflow of 1,735.96 thousand yuan over the past five days [1] Group 2 - In the latest quarterly report for Q1 2025, the company reported revenue of 280 million yuan, a year-on-year increase of 130%, and a net profit of 13.96 million yuan, a year-on-year increase of 0.58% [2] - The company's gross profit margin stands at 15.27% [2] - Shangrong Medical is recognized as a national high-tech enterprise and has received numerous awards and honors, including over 180 patents, which contribute to its ongoing development [1]
尚荣医疗收盘上涨2.57%,滚动市盈率150.86倍,总市值33.74亿元
Sou Hu Cai Jing· 2025-07-07 08:59
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Shangrong Medical, which has a current PE ratio of 150.86, significantly higher than the industry average of 51.42 [1][2] - As of July 7, Shangrong Medical's stock closed at 3.99 yuan, marking a 2.57% increase, with a total market capitalization of 3.374 billion yuan [1] - The company has seen a net inflow of 10.55 million yuan in principal funds on July 7, with a total inflow of 9.69 million yuan over the past five days [1] Group 2 - Shangrong Medical reported a revenue of 280 million yuan for Q1 2025, reflecting a year-on-year increase of 30% [2] - The net profit for the same period was 13.96 million yuan, showing a year-on-year growth of 0.58%, with a sales gross margin of 15.27% [2] - The company is recognized as a national high-tech enterprise and has accumulated over 180 patents, which contribute to its ongoing development [1]
尚荣医疗收盘上涨3.67%,滚动市盈率138.76倍,总市值31.03亿元
Sou Hu Cai Jing· 2025-06-23 08:57
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Shangrong Medical, indicating a significant increase in stock price and a high PE ratio compared to industry averages [1][2] - As of June 23, Shangrong Medical's stock closed at 3.67 yuan, up 3.67%, with a rolling PE ratio of 138.76 times and a total market value of 3.103 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 48.89 times and a median of 35.79 times, placing Shangrong Medical at the 111th position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, Shangrong Medical reported an operating income of 280 million yuan, a year-on-year increase of 30%, and a net profit of 13.9642 million yuan, reflecting a year-on-year growth of 0.58% [2] - The company's sales gross margin stands at 15.27% [2] - Shangrong Medical is recognized as a national high-tech enterprise and has received numerous awards and honors, including over 180 patents, which contribute to its ongoing development [1]
尚荣医疗收盘下跌2.43%,滚动市盈率136.87倍,总市值30.61亿元
Sou Hu Cai Jing· 2025-05-26 08:54
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Shangrong Medical, indicating a significant disparity between its price-to-earnings (PE) ratio and the industry average [1][2] - As of May 26, the closing price of Shangrong Medical was 3.62 yuan, with a PE ratio of 136.87, significantly higher than the industry average of 48.92 [1][2] - The company's total market capitalization is reported at 30.61 billion yuan, ranking it 111th in the medical device industry [1][2] Group 2 - For Q1 2025, Shangrong Medical reported an operating income of 280 million yuan, reflecting a year-on-year increase of 1.30%, and a net profit of 13.96 million yuan, with a slight increase of 0.58% [2] - The sales gross margin for the company stands at 15.27% [2] - The company has a total of 58,323 shareholders, with an average holding value of 352,800 yuan and an average shareholding quantity of 27,600 shares [1]
尚荣医疗收盘下跌1.32%,滚动市盈率141.78倍,总市值31.71亿元
Sou Hu Cai Jing· 2025-05-20 08:50
Company Overview - Shangrong Medical's closing price on May 20 was 3.75 yuan, down 1.32%, with a rolling PE ratio of 141.78 times and a total market value of 3.171 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 49.51 times and a median of 36.17 times, placing Shangrong Medical at the 111th position in industry rankings [1][2] - The main business activities include the production and sales of medical products, medical services, and health industry operations [1] Financial Performance - For Q1 2025, the company reported revenue of 280 million yuan, a year-on-year increase of 1.30%, and a net profit of 13.9642 million yuan, reflecting a year-on-year growth of 0.58% [2] - The sales gross margin for the same period was 15.27% [2] Market Position - The company has been recognized as one of the earliest to introduce clean technology into hospital operating rooms in China [1] - Shangrong Medical has received multiple honors, including national key new product recognition and various awards from local government bodies, highlighting its innovation and technological advancements [1] - The company holds over 180 patents, which are crucial for its ongoing development [1]
尚荣医疗收盘上涨10.00%,滚动市盈率137.24倍,总市值30.69亿元
Sou Hu Cai Jing· 2025-05-12 09:00
Core Viewpoint - Shangrong Medical's stock price closed at 3.63 yuan, up 10.00%, with a rolling PE ratio of 137.24, marking a new low in 95 days, and a total market value of 3.069 billion yuan [1] Group 1: Financial Performance - For Q1 2025, the company reported revenue of 280 million yuan, a year-on-year increase of 1.30%, and a net profit of 13.9642 million yuan, a year-on-year increase of 0.58% [2] - The company's gross profit margin stands at 15.27% [2] Group 2: Market Position - In the medical device industry, the average PE ratio is 49.84, and the median is 36.59, placing Shangrong Medical at the 110th position [1][2] - The company's PE (TTM) is 137.24, while the static PE is 137.74, and the price-to-book ratio is 1.16 [2] Group 3: Business Overview - Shangrong Medical primarily engages in the production and sales of medical products, medical services, and health industry operations, including medical engineering, medical equipment sales, and hospital logistics management [1] - The company is recognized as one of the earliest to introduce clean technology into hospital operating rooms and has received multiple honors, including national key new product recognition and various awards from local government [1] - The company holds over 100 patents, contributing to its continuous development and innovation [1]
尚荣医疗收盘下跌9.86%,最新市净率1.00,总市值26.29亿元
Sou Hu Cai Jing· 2025-04-07 09:36
序号股票简称PE(TTM)PE(静)市净率总市值(元)17尚荣医疗-17.81-17.661.0026.29亿行业平均 43.3345.624.5697.92亿行业中值27.8027.182.1643.48亿1硕世生物-1656.84-1656.841.0434.23亿2诺唯 赞-492.44-492.442.1383.72亿3博晖创新-330.51-203.493.6450.73亿4康泰医学-246.4728.922.5247.94亿5华 大基因-184.88202.231.91187.87亿6奥精医疗-100.70-100.701.2818.25亿7睿昂基因-72.56-72.561.1310.50亿 8华大智造-52.90-52.903.97316.93亿9热景生物-49.53-49.532.7288.78亿10中红医疗-45.21-30.750.7240.25亿 11天智航-37.71-37.713.9446.42亿 来源:金融界 截至2024年三季报,共有29家机构持仓尚荣医疗,其中基金29家,合计持股数365.00万股,持股市值 0.11亿元。 深圳市尚荣医疗股份有限公司主要业务是医疗产品生产销售 ...